HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.
July 26, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Karyopharm Therapeutics and maintained a $10 price target.
The reiteration of a 'Buy' rating by HC Wainwright & Co. indicates their continued confidence in Karyopharm Therapeutics. The maintained price target of $10 suggests that they believe the stock is undervalued at current prices. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100